Clinical

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.

A serum level is a snapshot, while genotype is the blueprint. Relying on levels alone misses carriers and mislabels patients, and the resulting diagnostic gap carries real clinical and economic costs.

AATD is better understood as a genetic predisposition than a single disease. Genotype, codominant inheritance, and environmental exposure together shape who develops lung or liver disease and how severe it becomes.

Before comparing therapies, clinicians need the statistical vocabulary: what a p-value actually measures, why effect size matters more, and how network meta-analysis links trials through a shared placebo comparison.

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.

A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.

The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.

A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.

In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

Led by the moderator, the expert neurology and primary care panelists examined the gap between expanded coverage and real-world access.

Led by the moderator, the panelists discussed how they sequence plasma p-tau217 and beta-amyloid 42/40 testing alongside cognitive screening as a first-line workup, reserving confirmatory amyloid PET or CSF testing for inconclusive cases, and noted that payer coverage for these biomarker tests has so far been largely free of denials.

The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.

Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.